GPC3-Gerichtetes Arzneimittel, das einem Patienten Verabreicht Wird, der auf die GPC3-Gerichtete Arzneimitteltherapie Reagiert

Details

Veröffentlichungs-Nr.

EP3557260

Aktenzeichen

EP19176006

Anmeldetag

24. Dezember 2013

Veröffentlichung

18. Mai 2022

Erteilung

18. Mai 2022

Rechtsraum

EP

IPC

G01N33/574A61K39/395A61K45/00A61P1/16A61P35/00G01N33/48G01N33/53C07K16/30

Abstract

The present invention discloses a method for determining the efficacy of GPC3-targeting drug therapy for cancer in a patient before the start of GPC3-targeting drug therapy or a patient or determining the continuation of GPC3-targeting drug therapy for a patient, including monitoring a concentration of free GPC3 in a biological sample isolated from the patient before the start of GPC3-targeting drug therapy and/or the patient treated with the GPC3-targeting drug therapy, wherein when the concentration of free GPC3 is a predetermined value, the efficacy of the GPC3-targeting drug therapy is determined or the continuation of the GPC3-targeting drug therapy is determined. The present invention also discloses a GPC3-targeting drug or a preparation which is to be further administered to a patient for which the efficacy of the GPC3-targeting drug therapy has been determined or the continuation of the GPC3-targeting drug therapy has been determined.

Anmelder

Firmen

CHUGAI SEIYAKU KABUSHIKI KAISHA
F. Hoffmann-La Roche AG

Land

🇯🇵 Japan

Fachgebiete